SARMs

LGD-3033

One digit from a real compound, and an empty record of its own

7 sections

Top of article
What it actually is
What it is supposed to do
What people take it for
The dose question
How to check you have the right molecule
What people get wrong
What is known about harm

What circulates: I found no dosing figure traceable to anything
What was studied: Nothing, in any species
The gap: No published human dose to compare against
How long it lasts: I could not find one. There is no compound-specific pharmacology under this name to measure.

What it actually is

LGD-3033 is a name with no compound behind it that the searches behind the class page could find. A PubMed search returns zero records under LGD-3033 or LGD3033, and ClinicalTrials.gov returns none. The only database entry the name produces is PubChem's record for LGD-3303, one digit away, where LGD-3033 appears among the synonyms supplied by whoever deposited the record.

What it is supposed to do

Nothing published describes what LGD-3033 does at any receptor. What is known about LGD-3303, the compound one digit away, is that it is a tricyclic pyrroloquinolinone studied in rats, and that is a different chemotype from LGD-4033.

What people take it for

Sold as a successor to LGD-4033. Nothing in the published record supports the succession or, as far as the searches went, the existence of a separate compound.

The dose question

What circulates: I found no dosing figure traceable to anything
What was studied: Nothing, in any species; Searched under LGD-3033 and LGD3033 on 10 August 2026

No studied dose to compare

There is nothing to compare against, and the name is the whole problem. A PubMed search returns zero records under either spelling, and the only database entry the name produces is PubChem's record for LGD-3303, one digit away, where LGD-3033 sits among depositor supplied synonyms. LGD-3303 is a different chemotype, it is the earlier compound in the literature rather than a successor, and the papers on it are in rats. A European laboratory network lists both spellings in one scope line; the American watch list and a 2019 Senate bill carry only LGD-3303.

Reported because it is what people use. Nothing here recommends any amount.

How long it lasts

I could not find one. There is no compound-specific pharmacology under this name to measure.

Route studied

None found in any species under this spelling. LGD-3303, the neighbouring name, has been studied in rats.

Route used

By mouth, in the way the other compounds on this shelf are taken. I found no published dosing figure to report.

How to check you have the right molecule

This is the identity check. If a seller offers LGD-3033, ask what it resolves to, because the name returns no paper, no trial and no chemical record of its own. Note also that LGD is a company prefix rather than a compound family, so a name beginning that way says who filed it rather than what it does.

Walked through on two real certificates in how to read a certificate of analysis.

What people get wrong

One digit separates this name from a real compound with published rat pharmacology, and documents disagree about whether they are the same thing. A European laboratory network lists both spellings in one scope line, while the American watch list and a 2019 Senate bill carry only LGD-3303. Where official documents cannot agree that two names are two things, a shopper has no way to.

What is known about harm

Nothing published says it is harmful, because nothing published says anything about it. An empty file is not a clean one, and a blank should not be read as reassurance.

Others in SARMs

Everything on this page is a summary. The citations, the studies and the reasoning live in the full entry.

Read the full entry on LGD-3033

Get the next one in your inbox

Free. One email a week at most. Unsubscribe in one click.

Double opt-in · No spam · Unsubscribe anytime